The Cancer Drug Development Forum (CDDF) will hold a live webinar on “CDDF Live Webinar series – AI and Big Data AI in Drug Development: Transparency and Risk Assessment” on 16 June at 16:00 CET. This webinar will include a lecture by Dr. Weida Tong (FDA) followed by a 30-minute panel discussion moderated by Ruth Plummer (CDDF).
WEBINAR OUTLINE
There has been a rapidly increasing use of AI tools across all areas of cancer drug development, from medicinal chemistry to modelling of patient cohorts. Dr Tong is Director of the Division of Bio-informatics and Biostatistics at the FDA and his primary research interests are the application of bioinformatics, Artificial Intelligence (AI), molecular modelling, and data analytics across all areas of drug development, with a focus on toxicology and drug safety.
LEARNING EXPECTATIONS
- To understand the use of AI in regulatory Science
- To learn about the global collaboration and Taskforce to assess AI readiness for use in drug regulation
- To understand the categories of AI tools used in regulatory science
Agenda: (CET time zone)
16:00 – 16:05 Welcome note – Ruth Plummer (CDDF)
16:05 – 16:30 Lecture by Dr Weida Tong (FDA)
16:30 – 17:00 Panel discussion – moderated by Ruth Plummer (CDDF)
WEBINAR OUTPUT
Dr. Weida Tong
Dr. Weida Tong is the director of the Division of Bioinformatics and Biostatistics at FDA’s National Center for Toxicological Research (NCTR). He has held the position of FDA Senior Biomedical Research and Biomedical Product Assessment Service (SBRBPAS) Expert, formerly known as Senior Biomedical Research Service, since 2011. Additionally, he has served as the chair of the Global Coalition for Regulatory Science Research (GCRSR)— an international coalition comprising approximately 20 regulatory agencies worldwide from over ten countries—since 2022. Dr. Tong holds the roles of founder and Chair Emeritus of the International MAQC (Massive Analysis and Quality Control) Society. He also lends his expertise to Science Advisory Boards for numerous multi-institutional projects in both Europe and the U.S. Furthermore, he maintains adjunct appointments at several universities. Dr. Tong’s contributions to the field are evidenced by his publication of over 300 peer-reviewed papers and book chapters.